Next 10 |
home / stock / vphif / vphif news
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
2024-06-13 07:31:33 ET More on Valeo Pharma Historical earnings data for Valeo Pharma Financial information for Valeo Pharma Read the full article on Seeking Alpha For further details see: Canada's Valeo Pharma cuts jobs amid push for cost savings
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...
VALEO PHARMA TO HOST SECOND QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , June 4, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, annou...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS Canada NewsWire MONTREAL , April 25, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announc...
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE Canada NewsWire MONTREAL , April 9, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB...
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS Canada NewsWire MONTREAL , March 22, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, t...
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS Canada NewsWire Q1-24 revenues of $13.5 million , up 3% over Q1-23 Q1-24 adjusted EBITDA loss of $2.1 million compared to $2.2 million for Q1-23, down 6% Total Enerzair and Atectura prescriptions for...
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , March 7, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, annou...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...